Search

Your search for "anpc" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline

September 14, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (‘CDA’) cancer detection technology and Roche’s FoundationOne […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical Device Product Registration

September 13, 2021

AnPac Bio-Medical Science Co., Ltd. has developed its proprietary Cancer Differentiation Analysis (“CDA”) technology to detect biophysical signals as an alternative early disease indicator to blood-based biomarker testing for cancer The company has laboratories and R&D facilities in China equipped for CDA testing and cancer biochemical testing, as well as a CLIA/CAP accredited laboratory in […]

News Articles

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

September 8, 2021

AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021 The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China A recent report […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding

September 7, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd., one of its subsidiaries; the increase came after approval was granted by the company audit committee and board of directors. The company announced that in late August 2021 it finalized the […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CLIA Laboratory Receives Accreditation from the College of American Pathologists

August 30, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its Philadelphia, Pennsylvania-based Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, initiated in the early 1960s, as being […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

August 26, 2021

Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Registration Testing of Its Multicancer CDA Device

August 23, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical device; the device, which has been tested and evaluated extensively, features AnPac’s proprietary Cancer Differentiation Analysis Technology (“CDA”). The company […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Seasoned Professional as US CEO

August 17, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective as of Aug. 16, 2021. The company noted that Pandit will lead AnPac Bio’s U.S. research and development efforts, as […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Cooperative and Partnership Agreements, and further Strengthens Board of Directors

Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., Ltd AnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices AnPac Bio’s board now includes Mr. Chao Feng who […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Featured in Coverage of Investor Summit Group’s Q3 Virtual Event

August 12, 2021

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, […]

InvestorNewsBreaks

InvestorNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

August 11, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021

August 6, 2021

Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1 The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screenings The global cancer diagnostics market size is […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Enters Strategic Collaboration to Explore Innovative Products and Medical Solutions

August 5, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced its entry into a cooperation agreement with Roche Pharmaceuticals China (“Roche”) to leverage both parties’ advantages and sources to explore novel health care and medical solutions and collaboration models in early cancer screening, early diagnosis and early treatment. […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

August 2, 2021

AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening CDA is powered by a database of over 200,000 samples and cases, providing a new way to […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science (NASDAQ: ANPC) Names New Independent Director

July 23, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced the appointment of Mr. Chao Feng as an independent director. Mr. Feng, a seasoned executive that has previously worked for two US Fortune 500 Companies in China, will be succeeding Ms. Lin Yu who resigned as a […]

Press Releases

AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device

August 23, 2021

PHILADELPHIA, Aug. 23, 2021 (GLOBE NEWSWIRE) — via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announces that the Company filed with China’s National Medical Products Administration (NMPA) on Aug. 19, 2021, for registration testing […]

Press Releases

AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO

August 17, 2021

PHILADELPHIA, Aug. 17, 2021 (GLOBE NEWSWIRE) — via InvestorWire — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announces that it has hired Dr. Sunil Pandit, a successful life sciences veteran and highly accomplished bio-medical scientist, as its […]

News Articles

Anpac Bio Continues Growth Trajectory

August 12, 2021

In recent years, advances in technology have led to demand for early cancer testing and screening methods that are less invasive and lower cost. Insurance companies have accepted that traditional testing methods are labor intensive and are not ideal as the first line of defense when screening and diagnosing cancer. This has opened a multi-billion-dollar […]

News Articles

AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening

August 4, 2021

Summary After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).